Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Stage IV
Interventions: DRUG: Datopotamab deruxtecan
Sponsor: Medical University of Vienna
Collaborators: Daiichi Sankyo